Patents by Inventor Paul Averback

Paul Averback has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6727278
    Abstract: Dense microspheres can be extracted and purified to substantial homogeneity from mammalian brain tissue, and used in the screening of therapies for potential effectiveness in impeding the formation of amyloid fibrils associated with Alzheimer's disease and other forms of cerebral amyloidosis. Compounds that, at in-tissue concentrations of 10−5 M or less, inhibit amyloid formation in a test animal injected intracerebrally with dense microspheres are particularly useful in inhibiting treating cerebral amyloidosis.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: April 27, 2004
    Assignee: DMS Pharmaceutical Inc.
    Inventor: Paul Averback
  • Publication number: 20040029809
    Abstract: The present invention relates to racemized proteins and racemized protein components of spherons that are useful for identifying compounds capable of preventing and/or ameliorating symptoms of Alzheimer's Disease and/or dementia associated with cerebral amyloidosis. The invention also relates to the compounds identified by the methods, and methods of treating and/or ameliorating symptoms of Alzheimer's Disease and/or dementia associated with cerebral amyloidosis. The invention also relates to methods of making an Alzheimer's Disease or dementia associated with cerebral amyloidosis animal model or test animal, the animal model produced therefrom, and to a method of using the animal model to screen for effective therapies.
    Type: Application
    Filed: May 23, 2003
    Publication date: February 12, 2004
    Inventor: Paul Averback
  • Publication number: 20040002460
    Abstract: The present invention relates to protein components of spherons that are useful for identifying compounds capable of preventing and/or ameliorating symptoms of Alzheimer's Disease and/or dementia associated with cerebral amyloidosis. The invention also relates to the compounds identified by the methods, and methods of treating and/or ameliorating symptoms of Alzheimer's Disease and/or dementia associated with cerebral amyloidosis. The invention also relates to methods of making an Alzheimer's Disease or dementia associated with cerebral amyloidosis animal model or test animal, the animal model produced therefrom, and to a method of using the animal model to screen for effective therapies.
    Type: Application
    Filed: March 4, 2003
    Publication date: January 1, 2004
    Inventor: Paul Averback
  • Publication number: 20030166569
    Abstract: The invention is directed to methods of treating conditions requiring removal or destruction of harmful or unwanted cells in a patient, such as benign and malignant tumors, using compounds containing or based on peptides comprising a part of the amino acid sequence of a neural thread protein.
    Type: Application
    Filed: November 15, 2002
    Publication date: September 4, 2003
    Inventors: Paul Averback, Jack Gemmell
  • Patent number: 6600947
    Abstract: Disclosed is a method of detecting amyloid-containing deposits in a mammal without administering exogenous chemicals such as fluorophores or chromophores. The method includes subjecting tissue of a mammal, preferably tissue of a mammal suspected of having at least one form of amyloidosis to autofluorescence-initiation, preferably by subjecting the tissue to at least excitation incident radiation from a light source having a wavelength of light within the range of from about 360 to about 370 nm, and more preferably to illumination incident radiation from a light source having wavelengths in the visible spectrum, to produce an emitted light signal beam and a reflected light signal beam. The method also preferably includes detecting the presence of emitted light having a wavelength of from about 400 nm to about 460 nm.
    Type: Grant
    Filed: March 16, 2001
    Date of Patent: July 29, 2003
    Assignee: Nymox Corporation
    Inventors: Paul A. Averback, Celine Dupuis
  • Publication number: 20030109437
    Abstract: The present invention relates to peptides, compositions, and methods of treating conditions requiring removal or destruction of harmful or unwanted cells in a patient, such as benign and malignant tumors, using proteins (and peptides derived from the amino acid sequences of such proteins), the amino acid sequence of which includes at least one amino acid sequence derived from neural thread proteins and other related molecules.
    Type: Application
    Filed: July 19, 2002
    Publication date: June 12, 2003
    Inventors: Paul Averback, Jack Gemmell
  • Publication number: 20030096350
    Abstract: The present invention is directed to methods of treating conditions requiring removal or destruction of harmful or unwanted cells in a patient, such as benign and malignant tumors, using peptides derived from the amino acid sequences of neural thread proteins and related molecules.
    Type: Application
    Filed: May 24, 2002
    Publication date: May 22, 2003
    Inventor: Paul Averback
  • Publication number: 20030096756
    Abstract: The present invention is directed to methods of treating conditions requiring removal or destruction of harmful or unwanted cells in a patient, such as benign and malignant tumors, using compounds containing or based on peptides comprising a part of the amino acid sequence of a neural thread protein.
    Type: Application
    Filed: July 19, 2002
    Publication date: May 22, 2003
    Inventor: Paul Averback
  • Publication number: 20030083298
    Abstract: Methods of treating and/or prophylaxis Alzheimer's disease by preventing the formation of cerebral amyloid due to the growth and disruption of dense microspheres (DMS) are disclosed utilizing medicaments that are effective in preventing or inhibiting the growth and disruption of DMS.
    Type: Application
    Filed: July 2, 2002
    Publication date: May 1, 2003
    Applicant: Nymox Corporation
    Inventor: Paul Averback
  • Publication number: 20030054990
    Abstract: The present invention is directed to methods of treating conditions requiring removal or destruction of harmful or unwanted cells in a patient, such as benign and malignant tumors, using neural thread proteins and related molecules.
    Type: Application
    Filed: March 8, 2002
    Publication date: March 20, 2003
    Applicant: Nymox Pharmaceutical Corporation
    Inventor: Paul Averback
  • Patent number: 6518314
    Abstract: Compositions comprising a pharmaceutically effective amount of a compound that impedes disruption of intact dense microspheres (DMS) by acting on DMS either to prevent disruption, or if disrupted, act on pre-disrupted DMS in such a way that, when the composition is administered to a test animal that has received an injection of DMS, it reduces the mean volume of tissue occupied by disrupted DMS, reduces the ratio of the number of inflammatory cells per DMS, or increases the ratio of the number of macrophages containing disrupted DMS per DMS, are useful for treating cerebral amyloidosis.
    Type: Grant
    Filed: October 6, 2000
    Date of Patent: February 11, 2003
    Assignee: Nymox Corporation
    Inventors: Paul Averback, Hossein Ghanbari, Iraj Beheshti, David Morse
  • Publication number: 20030003445
    Abstract: Disclosed is a method of preventing, inhibiting, and/or ameliorating cell death and/or tissue necrosis in live tissue containing neural thread proteins (NTP) by contacting the live tissue with at least an antibody, antibody fragment or antibody derivative that recognizes or binds to NTP, where the antibody, antibody fragment or antibody derivative is present in an amount effective to prevent, inhibit, reduce, control and/or ameliorate cell death and/or tissue necrosis. The method is capable of treating conditions requiring prevention, inhibition, reduction, control and/or amelioration of cell death and/or tissue necrosis caused by the presence of NTP.
    Type: Application
    Filed: May 6, 2002
    Publication date: January 2, 2003
    Inventor: Paul A. Averback
  • Publication number: 20030004107
    Abstract: Disclosed is a method of preventing, inhibiting, and/or ameliorating cell death and/or tissue necrosis in live tissue by contacting live tissue with at least a segment of NTP, or homologue, variant, derivative or mimetic thereof, where the segment of NTP, or homologue, variant, derivative or mimetic thereof is present in an amount effective to prevent, inhibit, and/or ameliorate cell death and/or tissue necrosis. The method is capable of treating conditions requiring prevention, inhibition, and/or amelioration of cell death and/or tissue necrosis.
    Type: Application
    Filed: May 16, 2002
    Publication date: January 2, 2003
    Inventor: Paul A. Averback
  • Publication number: 20020177778
    Abstract: Disclosed is a method of detecting amyloid-containing deposits in a mammal without administering exogenous chemicals such as fluorophores or chromophores. The method includes subjecting tissue of a mammal, preferably tissue of a mammal suspected of having at least one form of amyloidosis to autofluorescence-initiation, preferably by subjecting the tissue to at least excitation incident radiation from a light source having a wavelength of light within the range of from about 360 to about 370 nm, and more preferably to illumination incident radiation from a light source having wavelengths in the visible spectrum, to produce an emitted light signal beam and a reflected light signal beam. The method also preferably includes detecting the presence of emitted light having a wavelength of from about 400 nm to about 460 nm.
    Type: Application
    Filed: March 16, 2001
    Publication date: November 28, 2002
    Inventors: Paul A. Averback, Celine Dupuis
  • Patent number: 6461608
    Abstract: The present invention is directed to novel bacteriophage compositions useful in treating food products to prevent bacterial contamination.
    Type: Grant
    Filed: November 22, 2000
    Date of Patent: October 8, 2002
    Assignee: Nymox Pharmaceutical Corporation
    Inventors: Paul Averback, Jack Gemmell
  • Patent number: 6413940
    Abstract: Methods of treating and/or prophylaxis Alzheimer's disease by preventing the formation of cerebral amyloid due to the growth and disruption of dense microspheres (DMS) are disclosed utilizing medicaments that are effective in preventing or inhibiting the growth and disruption of DMS.
    Type: Grant
    Filed: February 3, 1998
    Date of Patent: July 2, 2002
    Assignee: Nymox Corporation
    Inventor: Paul Averback
  • Publication number: 20020028473
    Abstract: DMS present in the brain of individuals susceptible to cerebral amyloidosis disintegrate into DMS components to form cerebral amyloid plaques and other DMS components that are removed from the brain via circulating bodily fluids. Detecting the presence of these removed DMS components and/or antibodies thereto in circulating bodily fluids provides a diagnostic mechanism to determine the onset of cerebral amyloid plaque formation. Detecting the presence of these removed DMS components and/or antibodies thereto in circulating bodily fluids also provides a diagnostic mechanism to determine the efficacy of treatment regimes for preventing cerebral amyloid plaque formation. Antibodies also can be raised against isolated DMS components and subsequently utilized in a diagnostic method capable of detecting the onset of cerebral amyloid plaque formation.
    Type: Application
    Filed: October 29, 2001
    Publication date: March 7, 2002
    Inventor: Paul Averback
  • Patent number: 6309892
    Abstract: DMS present in the brain of individuals susceptible to cerebral amyloidosis disintegrate into DMS components to form cerebral amyloid plaques and other DMS components that are removed from the brain via circulating bodily fluids. Detecting the presence of these removed DMS components and/or antibodies thereto in circulating bodily fluids provides a diagnostic mechanism to determine the onset of cerebral amyloid plaque formation. Detecting the presence of these removed DMS components and/or antibodies thereto in circulating bodily fluids also provides a diagnostic mechanism to determine the efficacy of treatment regimes for preventing cerebral amyloid plaque formation. Antibodies also can be raised against isolated DMS components and subsequently utilized in a diagnostic method capable of detecting the onset of cerebral amyloid plaque formation.
    Type: Grant
    Filed: June 10, 1996
    Date of Patent: October 30, 2001
    Assignee: Nymox Pharmaceutical Corporation
    Inventor: Paul Averback
  • Patent number: 6130221
    Abstract: Compositions comprising a pharmaceutically effective amount of a compound that impedes disruption of intact dense microspheres (DMS) by acting on DMS either to prevent disruption, or if disrupted, act on pre-disrupted DMS in such a way that, when the composition is administered to a test animal that has received an injection of DMS, it reduces the mean volume of tissue occupied by disrupted DMS, reduces the ratio of the number of inflammatory cells per DMS, or increases the ratio of the number of macrophages containing disrupted DMS per DMS, are useful for treating cerebral amyloidosis.
    Type: Grant
    Filed: May 19, 1997
    Date of Patent: October 10, 2000
    Assignee: Nymox Corporation
    Inventors: Paul Averback, Hossein Ghanbari, Iraj Beheshti, David Morse
  • Patent number: 6121036
    Abstract: Purified, host-specific, non-toxic, wide host range and virulent bacteriophage preparations that are effective in killing bacterial organisms in vivo are disclosed. Also disclosed are compositions containing these bacteriophages, methods of making the bacteriophage preparations and methods of treating bacterial infections using the compositions. Methods of treating bacterial infections using the compositions containing the bacteriophages in combination with conventional antibiotics also are disclosed.
    Type: Grant
    Filed: April 15, 1997
    Date of Patent: September 19, 2000
    Inventors: Hossein A. Ghanbari, Paul Averback